

---

# North Dakota Medicaid Pharmacy Program Quarterly News

---

*Published Quarterly by Health Information Designs, Inc.*

Fall 2009

Welcome to the Fall 2009 edition of the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, Inc. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, Inc. (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit [www.hidndmedicaid.com](http://www.hidndmedicaid.com), or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

The Fall 2009 newsletter provides information regarding recent prior authorization updates with instructions on downloading forms and criteria from the HID North Dakota Medicaid website. Other information provided in the fall newsletter includes recent Medicaid Pharmacy updates as well as significant new dosage forms approved in 2009.

The North Dakota Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, Inc. at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at [info@hidinc.com](mailto:info@hidinc.com).



### Helpful Numbers

PA Help Desk                    866-773-0695  
To fax PAs                        866-254-0761  
To report adverse                800-FDA-1088  
reactions (via Med Watch)

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Prior Authorization Updates	2
Pharmacy Updates	2
Significant New Dosage Forms of 2009	3
Health Information Designs, Inc.	4

**Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, [www.hidndmedicaid.com](http://www.hidndmedicaid.com).**

## Prior Authorization Updates

Effective January 1, 2010, the North Dakota Medicaid Agency updated the prior authorization program to reflect the recent Drug Utilization Review (DUR) Committee recommendations. The updates are listed below:

Drug or Class	Criteria for coverage	Covered options not requiring PA
Blood Factor Products	<ul style="list-style-type: none"> <li>Annual visit with accredited Hemophilia Treatment Center</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
Nucynta	<ul style="list-style-type: none"> <li>Unable to tolerate other opioids due to gastrointestinal side effects</li> </ul>	<ul style="list-style-type: none"> <li>Oxycodone, oxymorphone, hydro-morphone and meperidine</li> </ul>
Nuvigil	<ul style="list-style-type: none"> <li>FDA approved indication and failure of Provigil</li> </ul>	<ul style="list-style-type: none"> <li>Provigil</li> </ul>
Relistor	<ul style="list-style-type: none"> <li>Diagnosis of opioid-induced constipation</li> <li>Inability to tolerate oral medications <i>or</i></li> <li>Failed two oral medications</li> </ul>	<ul style="list-style-type: none"> <li>Polyethylene glycol powder and/or lactulose</li> </ul>
Sancuso	<ul style="list-style-type: none"> <li>Inability to tolerate oral medications <i>or</i></li> <li>Failed therapy on ondansetron or oral granisetron</li> </ul>	<ul style="list-style-type: none"> <li>Granisetron and ondansetron</li> </ul>

PA forms and criteria can be found on the HID North Dakota Medicaid website ([www.hidndmedicaid.com](http://www.hidndmedicaid.com)).

## Medicaid Pharmacy Update

### Blood Glucose Test Strips

Edits will be implemented in the near future to prevent blood glucose test strips from being billed on the medical side. These edits will require blood glucose test strips to be billed on pharmacy claims.

This will not impact Medicare Part B primary claims (or any other claims where other insurance requires billing on the medical side). Those can continue to be billed by current methods.

### Tablet Splitting

The department has participated in a number of newsletters and mailings to pharmacies and prescribers regarding the DUR Board's desire for Lipitor and Lexapro to be dispensed in the most efficient manner possible, including splitting tablets. Despite these mailings, there was no increase in the utilization of tablet splitting. Therefore, effective in February, we will be mandating tablet splitting for all Lexapro 5 mg and 10 mg doses, as well as all Lipitor 10 mg, 20 mg, and 40 mg doses.

One tablet splitter can be billed every three years for patients receiving Lipitor. The tablet splitter NDC will be 11822377360 and the amount reimbursed will be \$4.75. Reimbursement for tablet splitters will only occur if there is a claim for Lipitor 20, 40, or 80 mg tablets (#15 for a 30 day supply) within the last 45 days.

Overrides for patients currently on 1.5 tablets of Lipitor or Lexapro have been entered.

### Prescriber ID Numbers

In the near future, edits will be implemented requiring prescriber NPIs be billed on each claim. Please make sure that your pharmacy system will submit the physician NPI first before attempting to use the DEA number.

## Significant New Dosage Forms introduced in 2009

<b><u>Brand/Generic</u></b>	<b><u>Description</u></b>
Adcirca (tadalafil)	New formulation for pulmonary arterial hypertension.
Astepro (azelastine)	New 0.15% nasal spray for seasonal and perennial allergic rhinitis.
Caldolor (ibuprofen)	Injectable formulation for treatment of pain and fever.
Cambia (diclofenac)	Oral solution for acute treatment of migraine attacks.
Colcrys (colchicine)	First FDA-approved formulation of colchicine.
Cycloset (bromocriptine)	New 0.8 mg tablets for management of type 2 diabetes.
Edluar (zolpidem)	Sublingual formulation for insomnia.
Embeda (morphine/naltrexone)	Analgesic for around-the-clock management of moderate to severe pain.
Feraheme (ferumoxytol)	Intravenous iron replacement for anemia of chronic kidney disease.
Gelnique (oxybutynin)	Topical gel for treatment of overactive bladder.
Intuniv (guanfacine)	New extended-release tablets for treatment of ADHD.
Invega Sustenna (paliperidone)	Once-monthly injectable formulation for acute/maintenance treatment of schizophrenia.
Kapidex (dexlansoprazole)	The R-enantiomer of lansoprazole for erosive esophagitis and heartburn associated with non-erosive GERD.
Lamictal ODT (lamotrigine)	New orally disintegrating tablets (ODT).
Lamictal XR (lamotrigine)	Extended-release formulation for partial onset seizures.
Lipsovir (acyclovir/hydrocortisone)	Topical cream for early treatment of recurrent cold sores.
Lysteda (tranexamic acid)	Tablet formulation for heavy menstrual bleeding.
Metozolv ODT (metoclopramide)	Orally disintegrating tablets for symptoms associated with diabetic gastroparesis and short-term treatment of GERD.
Onsolis (fentanyl)	New buccal soluble film formulation for breakthrough cancer pain.
Pennsaid (diclofenac)	New topical NSAID solution for osteoarthritis of the knee.
Plan B One-Step (levonorgestrel)	New single dose emergency contraceptive.
Prevacid 24HR (lansoprazole)	Over-the-counter PPI for treatment of heartburn.
Qutenza (capsaicin)	A prescription patch formulation for postherpetic neuralgia pain.
Revatio (sildenafil)	New injectable formulation for pulmonary arterial hypertension.
Sumavel DosePro (sumatriptan)	New needle-free subcutaneous delivery system for acute treatment of migraines and cluster headaches.
Synvisc-One (hylan G-F 20)	New single-injection formulation for osteoarthritis of the knee.
Temodar (temozolomide)	New intravenous formulation for glioblastoma and anaplastic astrocytoma.
Twynsta (telmisartan/amlodipine)	New ARB and calcium channel blocker combination for treatment of hypertension.
Tyvaso (treprostinil)	Inhalation formulation for the treatment of pulmonary arterial hypertension.
Valturna (aliskiren/valsartan)	New combination direct renin inhibitor plus ARB for hypertension.
Vectical (calcitriol)	Topical ointment for treatment of plaque psoriasis.
Zipsor (diclofenac)	New liquid filled capsule formulation for mild to moderate acute pain.
Zirgan (ganciclovir)	Ophthalmic gel for acute herpetic keratitis (dendritic ulcers).



Health Information Designs, Inc. (HID) is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.

For 33 years, HID has worked to improve the quality and cost effectiveness of health care through clinically rational use of prescription medication. Our clients include public and private healthcare plans throughout the U.S. with a combined total of over 14 million covered lives.

Health Information Designs, Inc. was founded in 1976 and is incorporated as a C Corporation in the State of Delaware. HID's initial mission was to market drug utilization review (DUR) services nationally and since its founding, has provided DUR services for clients in approximately two-thirds of the United States. HID is headquartered in Auburn, Alabama, with regional offices in Arkansas, Maryland, and Mississippi.



391 Industry Drive  
Auburn, AL 36832  
Tel: 800-748-0130  
Fax: 800-748-0116

PRST STD  
U.S.  
Postage